Wenxin Tong

Dr. Wenxin Tong

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
ASAshot Sargsyan
Ashot Sargsyan
LDLudivine Doridot
Ludivine Doridot
SHSarah A. Hannou
Sarah A. Hannou
WTWenxin Tong
Wenxin Tong
HSHarini Srinivasan
Harini Srinivasan
MHMark Herman
Mark Herman
Carbohydrate response element–binding protein (ChREBP) is a carbohydrate-sensing transcription factor that regulates both adaptive and maladaptive genomic responses in coordination of systemic fuel homeostasis. Genetic variants in the ChREBP locus associate with diverse metabolic traits in humans, including circulating lipids. To identify novel ChREBP-regulated hepatokines that contribute to its systemic metabolic effects, we integrated ChREBP ChIP-Seq analysis in mouse liver with human genetic and genomic data for lipid traits and identified hepatocyte growth factor activator (HGFAC) as a promising ChREBP-regulated candidate in mice and humans. HGFAC is a protease that activates the pleiotropic hormone hepatocyte growth factor. We demonstrate that HGFAC-KO mice had phenotypes concordant with putative loss-of-function variants in human HGFAC. Moreover, in gain- and loss-of-function genetic mouse models, we demonstrate that HGFAC enhanced lipid and glucose homeostasis, which may be mediated in part through actions to activate hepatic PPARγ activity. Together, our studies show that ChREBP mediated an adaptive response to overnutrition via activation of HGFAC in the liver to preserve glucose and lipid homeostasis.

18 October 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
LDLudivine Doridot
Ludivine Doridot
SHSarah Anissa HANNOU
Sarah Anissa HANNOU
SKSarah A. Krawczyk
Sarah A. Krawczyk
WTWenxin Tong
Wenxin Tong
MKMi-Sung Kim
Mi-Sung Kim
MHMark Herman
Mark Herman
The metabolic syndrome (MetS), defined as the co-occurrence of disorders including obesity, dyslipidemia, insulin resistance, and hepatic steatosis, has become increasingly prevalent in the world over recent decades. Dietary and other environmental factors interacting with genetic predisposition are likely contributors to this epidemic. Among the involved dietary factors, excessive fructose consumption may be a key contributor. When fructose is consumed in large amounts, it can quickly produce many of the features of MetS both in humans and mice. The mechanisms by which fructose contributes to metabolic disease and its potential interactions with genetic factors in these processes remain uncertain. Here, we generated a small F2 genetic cohort of male mice derived from crossing fructose-sensitive and -resistant mouse strains to investigate the interrelationships between fructose-induced metabolic phenotypes and to identify hepatic transcriptional pathways that associate with these phenotypes. Our analysis indicates that the hepatic transcriptional pathways associated with fructose-induced hypertriglyceridemia and hyperinsulinemia are distinct from those that associate with fructose-mediated changes in body weight and liver triglyceride. These results suggest that multiple independent mechanisms and pathways may contribute to different aspects of fructose-induced metabolic disease.

29 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAshot Sargsyan
Ashot Sargsyan
LDLudivine Doridot
Ludivine Doridot
SHSarah A. Hannou
Sarah A. Hannou
WTWenxin Tong
Wenxin Tong
HSHarini Srinivasan
Harini Srinivasan
MHMark Herman
Mark Herman
Carbohydrate Responsive Element-Binding Protein (ChREBP) is a carbohydrate sensing transcription factor that regulates both adaptive and maladaptive genomic responses in coordination of systemic fuel homeostasis. Genetic variants in the ChREBP locus associate with diverse metabolic traits in humans, including circulating lipids. To identify novel ChREBP-regulated hepatokines that contribute to its systemic metabolic effects, we integrated ChREBP ChIP-seq analysis in mouse liver with human genetic and genomic data for lipid traits and identified Hepatocyte Growth Factor Activator (HGFAC) as a promising ChREBP-regulated candidate in mice and humans. HGFAC is a protease that activates the pleiotropic hormone Hepatocyte Growth Factor (HGF). We demonstrate that HGFAC KO mice have phenotypes concordant with putative loss-of-function variants in human HGFAC. Moreover, in gain- and loss-of-function genetic mouse models, we demonstrate that HGFAC enhances lipid and glucose homeostasis, in part, through actions to activate hepatic PPARγ activity. Together, our studies show that ChREBP mediates an adaptive response to overnutrition via activation of an HGFAC-HGF-PPARγ signaling axis in the liver to preserve glucose and lipid homeostasis.

20 October 2026 in JCI Insight
Verified
Journal Article
Open access
PDF file
JAJie An
Jie An
JCJessica Cannavino
Jessica Cannavino
AWAshley Williams
Ashley Williams
ABAkshay Bareja
Akshay Bareja
WTWenxin Tong
Wenxin Tong
CNChristopher B. Newgard
Christopher B. Newgard
Exposure of humans to food insecurity (FI), involving sporadic access and low nutritional quality, is associated with later life development of metabolic disease phenotypes, but mechanisms are poorly understood. We exposed very young rats to a 20-day FI intervention or ad-lib (AL) feeding, using either standard chow (SC) or high fat/high sucrose (HF/HS) diets, followed by continued AL feeding on the respective diets for 10-13 weeks. We found that male, but not female rats subjected to FI on the HF/HS diet had increased body fat percentage, ratio of adipose to body weight, and fat cell size compared to AL rats, coupled with metabolomic and transcriptomic profiles consistent with reduced fatty acid oxidation in the liver and maladaptive remodeling of adipose tissue. These changes were specific to HF/HS feeding and did not occur with SC diet. Our study defines sex- and diet-specific metabolic remodeling responses to FI that may contribute to future disease phenotypes.